Bodily fluid and electrolyte homeostasis is a fundamental physiological function associated with numerous diseases when aberrant. The systemic fluid and electrolyte composition is regulated by the kidney. In addition, all secretory epithelia generate biological fluids with defined electrolyte composition essential for their specific functions. Fluid and electrolyte composition is determined by vectorial ion transport and the associated osmotic water transport through water channels. Many central and peripheral regulatory inputs ensure tight regulation of bodily fluid and electrolyte composition that respond to systemic, tissue, and cellular changes in fluid volume and electrolyte composition (39). A major regulatory pathway that immerged in the last several years is regulation of ion transporters by the WNK/SPAK kinases and IRBIT/PP1 pathways, the subject of this review. Seminal discoveries in this topic include identification of the WNK kinases in a search for MAPK/ ERK homologs (54) , the finding that mutations in the WNKs are associated with hypertension (52) , the association between the WNK and SPAK/OSR1 kinases and their function in a common regulatory pathway (19, 50) , and the regulation of the Na ϩ -HCO 3 Ϫ cotransporter NBCe1-B by IRBIT (47). Several aspects of these topics have been covered by extensive recent reviews (11, 34). Here, we will focus on the relationship between the WNK/SPAK and IRBIT/PP1 pathways to suggest that their reciprocal effect on fluid and electrolyte transport may form a common pathway that determines the resting and stimulatory secretory states.
The WNK Kinases as Scaffolding Proteins
The With-No lysine (K) Kinases (WNK) received their name due to the lack of the conserved lysine in subdomain II (27). The crystal structure of the kinase domain of WNK1 revealed that the lysine is contributed by a lysine in subdomain I (37). Mammals have four WNK kinases (FIGURE 1A) with several splice variants (34), with wide expression of WNK1 (9, 38) and WNK4 (28, 48) and more restricted and cell-specific expression of WNK2 (48) and WNK3 (48). The WNKs are very large proteins composed of up to 2,382 residues (WNK1). However, very little is known about their domain structure beyond the homologous kinase domain, the autoinhibitory domain (AID), and the multiple coiled-coil domains. WNKs 1, 2, and 4 also have several proline-rich domains (PRD) that in WNK1 play an important role in the regulation of the renal K ϩ channel ROMK1 (24). The WNKs PRD may also interact with SH3 domains to mediate WNK1-dependent endocytosis that is mediated by the endocytic scaffold intersectin (24). Notably, the PRDs of WNK1 and WNK4 also contain the PPxxF binding ligands for the scaffold proteins Homer (4) that may recruit them to GPCR complexes (53) . It is most likely that the WNKs have additional domains in the large stretches between the kinase domain and the COOH terminus (Ͼ1,800 residues in WNK1) that can function as scaffolds to mediate the many functions of the WNK kinases (27, 34, 50 
The SPAK/OSR1 Kinases
In many instances, the WNKs do not act directly on the transporters but rather phosphorylate the sterile 20 family stress kinases SPAK/OSR1 (11, 12). The domain structure of SPAK and OSR1 are depicted in FIGURE 1B. SPAK and OSR1 are related kinases FIGURE 1. The known domains of the WNKs, SPAK/OSR1, and IRBIT Known domains are marked only when first mentioned. For the WNKs, proline-rich domains (PRD) are in green, the coiled-coil domains (CCD) are in orange, the kinase domains are in red, the autoinhibitory domains (AID) are in purple, and the SPAK/OSR1 binding motifs [R/K]Fx[V/I] are in magenta. For the SPAK/OSR1, the proline-and arginine-rich domain (P/ARD) is in green, the kinase domain is in red, the serine-rich (S) motif is in purple, the WEW-containing domain that binds Cab39 is in pink, and the conserved COOH-terminal domain (CCT) is in brown. For IRBIT, the protein phosphatase 1 (PP1) binding motif is in green, the PEST domain is in red, the CCD is in orange, and the PDZ motif is in turquoise.
with conserved kinase domain, a serine-motif (Smotif), and a conserved COOH terminal (CCT) domain (44, 50 (56, 58) , and possibly the CLC2 Cl Ϫ channel, since the the CLC2 C. Elegans ortholog CLH3 is regulated by the kinases (10). The WNKs inhibit surface expression of NBCe1-B, Slc26a9 (16, 58) , and CFTR (56, 58) and the activity of all transporters. This is illustrated in FIGURE 2 , and the functional consequences are in 
IRBIT (IP 3 Rs Binding Protein Released With IP 3 )
Facilitation of ductal secretion by knockdown of the WNKs and SPAK (FIGURE 3A) suggests that they exert tonic inhibition of fluid and HCO 3 Ϫ secretion. Stimulation of secretions requires reversal of the inhibitory state. IRBIT/PP1 turned to the proteins that reverse the inhibitory effect of the WNKs/SPAK pathway and in addition to directly activate the transporters mediating epithelial fluid and HCO 3 Ϫ secretion.
IRBIT was discovered multiple times in different contexts, but it was only after the discovery that IRBIT binds to IP 3 Rs and dissociates from the IP 3 Rs by IP 3 (2) that we began to understand its role in epithelial transport. The various functions of IRBIT have been discussed recently (59), and here we limit the discussion to its role in ion transport. IRBIT comes in two forms. The short and long IRBIT are ubiquitous, with the long IRBIT being identical with the short IRBIT but with an NH 2 -terminal extension (3). The IRBIT domains identified so far are shown in FIGURE 1C and include a PP1 binding motif, a PEST domain, a coiled-coil domain, and a PDZ ligand at the end of the COOH terminus (15, 59) . The PEST domain has multiple phosphorylation sites (1) and is required for all IRBIT functions described so far (15, 59) .
As its name indicates, IRBIT interacts with all three IP 3 receptor isoforms to regulate their function (2, 13, REVIEWS PHYSIOLOGY • Volume 27 • October 2012 • www.physiologyonline.org 14) . IRBIT specifically interacts with the IP 3 binding domain in the NH 2 terminus of the IP 3 Rs (1). In fact, IRBIT competes with IP 3 for binding to the same site on IP 3 Rs and right shift the dose response for IP 3 binding, channel opening, and Ca 2ϩ release from ER in response to IP 3 (1, 13, 14) . These effects required phosphorylation of at least four serines in the PEST domain with phosphorylation of S68 being required for phosphorylation of the other sites (13) . The kinase(s) that phosphorylate IRBIT are not known at present, although IRBIT has consensus sites for PKD, AMPK, CamK-II-IV, and CK1 (15) . The PDZ ligand is required for interaction of IRBIT with the IP 3 Rs (14) 
-651, which show good homology with NBCe1-B(37-62) (JHH, unpublished observation), further pointing to this site as the IRBIT binding site. Notably, the autoinhibitory domain of the NCBT that binds IRBIT is not present in CFTR or the SLC26 transporters. This indicates that there are multiple IRBIT interacting domains and perhaps several mechanisms for activation of the transporters by IRBIT. Indeed, binding the IRBIT PEST domain is essential for its interaction with NBCe1-B but not with CFTR, although it is required for activation of both transporters (60) .
How might IRBIT activate the transporters? One mechanism can be by removal of autoinhibition. Information for such a mechanism is available only for NBCe1-B, and a similar mechanism may apply to the other NCBT with an autoinhibitory domain, like NBCe1-C, NBCn1, and NDCBE. However, note that the NH 2 terminus of NBCn1 and NDCBE is only partially conserved with that of NBCe1-B. Deletion analysis showed reduced inhibition of NBCe1-B by stepwise truncation of the NH 2 terminus, with complete removal of autoinhibition by deletion of the first 85 residues on NBCe1-B, defining the autoinhibitory domain as NBCe1-B(1-85) (32). The deletions also prevented activation of NBCe1-B by IRBIT with deletion of the first 16 residues was sufficient to eliminate activation of NBCe1-B by IRBIT (32). However, this study did not determine the effect of the deletions on IRBIT interaction with NBCe1-B, -62) and no binding to NBCe1-B(1-36). However, IRBIT binding was not observed with NBCe1-B(37-85), yet the possibility of IRBIT binding to NBCe1-B(37-62) or other sequences in this region was not examined (47). Hence, the most likely IRBIT binding domain is within NBCe1-B(37-62). Binding of IRBIT to this domain removes the autoinhibition to activate NBCe1-B.
In an attempt to gain additional information on the interaction between IRBIT and the autoinhibitory domain, we modeled the structure of the entire human NBCe1-B (NCBI ref. NP_001091954) NH 2 -terminus 400 amino acids using the ROBETTA online full-chain protein structure prediction server (29), which generated the model shown in FIGURE 4 . The green domain is predicted with high homology confidence (ROBETTA/Ginzu confidence score of 57.000) and is homologous to the NH 2 terminus of the crystal structure of human erythrocyte band-3 cytoplasmic domain (cdb3). A potential fold of residues 1-81 of NBCe1-B was predicted by ROBETTA utilizing de novo modeling source (confidence score of 2.094993). The first 62 residues that include the IRBIT binding region are shown in orange, and residues 63-100 are shown in blue. The turn-loop-␣-helix on the left includes residues 37-62. If the structure of NBCe1-B(1-81) resembles the actual structure, it is likely that the structure in FIGURE 4 represents the open state of NBCe1-B when bound to IRBIT, and the autoinhibitory siIRBIT FIGURE 3. WNKs and SPAK inhibit and IRBIT stimulates pancreatic duct fluid secretion Sealed pancreatic ducts in primary culture were treated with the indicated WNKs or SPAK siRNAs or the PP1 inhibitor tautomycin (A) or si-IRBIT (B) and were used to measure stimulated fluid secretion. Knockdown of the inhibitors WNKs and SPAK enhanced secretion, whereas inhibition of PP1 that is required to reverse the effect of the WNK/SPAK and knockdown of the activator IRBIT reduced secretion. The results were taken from Refs. 58, 60. domain is not inhibiting NBCe1-B. The turn-loop-␣-helix contains a stretch of conserved positive charges that may interact with the PEST domain that is required for interaction with and activation of NBCe1-B (47, 59, 60). One or the two helices in blue may function as a lever to swing the autoinhibitory domain toward the cdb3 homologous domain (green) to form the close autoinhibited state. It will be interesting to test several predictions of this model. As mentioned above, the IRBIT binding domain is not present in CFTR and SLC26 transporters, and thus they must be regulated by a different mechanism or by equivalent IRBIT binding domains.
IRBIT Antagonizes the Effects of the WNK/SPAK Pathway
Another mechanism by which IRBIT activates the HCO 3 Ϫ transport is antagonizing the effect of the WNK/SPAK pathway to restore surface expression of the internalized transporters. IRBIT has a PP1 binding site, and PP1 can dephosphorylate the Ser/ Thr residues phosphorylated by the WNKs/SPAK/ OSR1. Measurement of NBCe1-B (FIGURE 2A) and CFTR activity (FIGURE 2C) shows that IRBIT prevented the inhibition by both the WNK and the SPAK kinases and further activated the transporters. Analysis of surface expression showed that IRBIT reversed internalization of the transporters, restoring their normal surface expression (FIGURE 2, B AND D). It is of note that when activating the transporters or antagonizing the effect of the WNK/SPAK kinases IRBIT does not increase surface expression beyond the expression observed in the absence of the WNK/SPAK and IRBIT. This indicates that IRBIT has two effects on the transporters: antagonizing the internalizing effect of the WNK/SPAK kinases and activating the transporters. The central role of IRBIT in regulating the HCO 3 Ϫ transporters in vivo is shown in FIGURE 3B in which knockdown of IRBIT almost eliminated stimulated fluid secretion by the pancreatic duct. Moreover, the reduced secretion in the absence of IRBIT could be partially recovered by knockdown of SPAK (58), further emphasizing the interplay between the IRBIT/ PP1 and the WNK/SPAK pathways. In principal, IRBIT can reverse the effect of the WNK/SPAK kinases either by inhibition of endocytosis or by stimulation of exocytosis, both of which were shown to affect the WNK/SPAK-regulated transporters. For example, the WNKs regulate the surface expression of ROMK1 by activation of the intersectin-dependent endocytic pathway (24, 51). This effect is mediated by proline-rich domains in WNK1
1-119 that acts as a scaffold to recruit the endocytic complex to ROMK1 (24, 51). On the other hand, WNK4 acting through SPAK inhibited trafficking and exocytosis of NCC that was independent of dynamin (7, 23) and was reversed by dominant-negative sortilin that targets material to the lysosomes (62) . At present, it is not known whether IRBIT reverses the effect of the WNK/SPAK pathway by inhibition of endocytosis or stimulation of exocytosis. However, since WNK1 1-119 mediates the reduced surface expression of NBCe1-B and CFTR as was found with ROMK1, it is possible that IRBIT inhibits endocytosis to reverse the effect of the WNK/SPAK pathway.
PP1 and Calcineurin
Two phosphatases, PP1 and calcineurin (PP3, formally PP2B), have been identified as potential phosphatases that dephosphorylate Ser/Thr by the WNK/SPAK kinases to terminate their effect. Several ion transporters have a PP1 binding motif. This was reported for NKCC1 (18) , and a sequence search for PP1 binding motifs (45) revealed the presence of such motifs in NBCe1-B, NHE3, KCC, and ROMK1. In addition, WNK1 and WNK4 may have a PP1 binding site (49) . Moreover, the activity of NKCC1 (18, 20) , KCC (5), NBCe1-B, and CFTR (58) is affected by PP1. More recently, it was shown that the Ca 2ϩ -regulated phosphatase calcineurin regulates the phosphorylation and surface expression of NCC (26, 35). These effects may be mediated by dephosphorylation of WNK3 and WNK4 that displays increased phosphorylation in response to inhibition of calcineurin in vivo (26, 35). These findings suggest a prominent role for PP1, calcineurin, and likely other phosphatases in the regulation of the transporters regulated by the WNK/SPAK pathway.
The studies with NBCe1-B and CFTR suggest that IRBIT mediates the effects of PP1 (58) . Thus IRBIT has a PP1 binding site (13) and recruits PP1 to NBCe1-B and CFTR, which is required to reverse the effects of the WNK/SPAK and further activate the transporters (58) . Another recent study suggested that PP1 acts mainly on IRBIT to dephopshorylate IRBIT and inhibit activation of NBCe1-B by IRBIT when expressed in Xenopus oocytes that lack SPAK/OSR1 (32). The conclusion is based on mutation of the IRBIT PP1 binding motif to reduce or enhance binding of PP1. However, the effect of the mutations on interaction of IRBIT with PP1 and NBCe1-B was not examined. This finding is in contrast to the findings in mammalian cells where inhibition of PP1 by the native PP1 inhibitor I2 or the pharmacological inhibitor Tautomycin inhibited the transporters and acted similar to WNKs and SPAK (58) . In addition, mutation of the IRBIT PP1 binding site eliminated interaction of NBCe1-B and CFTR with PP1 (58) . Whether the presence of WNKs and SPAK/OSR1 in mammalian cells or other factors are responsible for the different findings is not clear.
Other scaffolds that recruit PP1 to ion transporters are members of the AATYK kinases. These kinases bind PP1 in a kinase-independent manner and interact with and dephosphorylate SPAK, resulting in inhibition of NKCC1 (20) . Interestingly, in addition to a PP1 binding site, IRBIT has the potential calcineurin binding motif LxVP that is located within the conserved AHCYL1 domain. Similarly, the AATYK kinases have an LxVP motif. It will be of interest to determine whether calcineurin regulates several of the transporters that are regulated In the resting state, SPAK is scaffold by WNK, which recruits SPAK to the HCO 3 Ϫ transporters. SPAK phosphorylates NBCe1-B, Slc26a6, and CFTR (indicated with red arrows and red -P) to sequester most of them in intracellular organelles (blue arrows), NBCe1-B in organelles next to the basolateral membrane, and Slc26a6 and CFTR likely in the same organelles next to the luminal membrane. In the absence of cytoplasmic IP 3 IRBIT is bound to the IP 3 receptors that in secretory cells are clustered at the apical pole. This results in low secretory activity. When the cells are stimulated with an IP 3 -generating agonist, IP 3 binds to the IP 3 receptors to dissociate IRBIT that now recruits PP1 to the transporters to dephosphorylate them. The organelles with the dephosphorylated transporters that are complexed with IRBIT now fuse with the plasma membrane to insert NBCe1-B in the basolateral membrane and Slc26a6 and CFTR in the luminal membrane. IRBIT remains bound to a specific site in each of the transporters in a mode similar to binding of IRBIT to the NH 2 terminus autoinhibitory domain of NBCe1-B. Insertion of the transporters in the plasma membrane and their activation by IRBIT results in stimulation of fluid and HCO 3 Ϫ secretion.
by the WNK/SPAK kinases and the role of IRBIT and AATYK in this form of regulation.The relationship between the WNK/SPAK and IRBIT/PP1 pathways in secretory epithelia discussed here is summarized in FIGURE 5 . The antagonistic effect of the WNK/SPAK and IRBIT/PP1 pathways raise the question of whether the mechanism in FIGURE 5 is a general mechanism and the two pathways form a regulatory pair to set the activity of ion transporters based on physiological demands. At present, we do not have information on whether IRBIT affects the activity of transporters other than NBCe1-B, CFTR, and the SLC26 transporters that are regulated by the WNK/ SPAK kinases, in particular the transporters that are associated with hypertension and K ϩ homeo- 
